GENB

Generate Biomedicines, Inc.
CAPPED RATING

Generate Biomedicines, Inc. (GENB) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.6 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.9
EV / EBITDA -5.4
Rev Growth YoY -37.7%
Gross Margin 0.0%
Price Return 3M -10.3%
Price Return 12M 6.6%
Catalyst Signal 0.00
Market Cap $1.7B
TTM Revenue $26.5M
Price / Sales 65.4
ROE N/A

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.6) D (1.3) D- (0.8) C (2.4) C+ (2.6) C- (2.0)
2026-11-05 C+ (2.6) D (1.3) D- (0.8) B- (2.9) C+ (2.7) C- (2.1)
2026-10-29 C+ (2.6) D (1.3) D- (0.8) B (3.4) C+ (2.7) C- (2.1)
2026-10-22 C+ (2.6) D (1.3) D- (0.8) B (3.3) C+ (2.6) C- (2.1)
2026-10-15 C+ (2.6) D (1.3) D- (0.8) B (3.2) C+ (2.6) C- (2.1)
Page 1 of 4